Introducing Tirzepatide: The Dual Advantage Tirzepatide represents a newer generation of incretin mimetic, distinguished by its unique dual-action mechanism
GLP-1 medications are also known as GLP-1 receptor agonists (GLP-1 RAs), which imitate the natural GLP-1 hormone, responsible for regulating our blood sugar levels, insulin, and hunger
After approval, your preauthorized card will be charged, and a shipping label will be created
Beneficiaries need to meet at least one of the following, based on their BMI and health history when they first started GLP-1 therapy: A BMI of 35 or higher A BMI of 30 or higher, with a history of heart failure, uncontrolled hypertension, or chronic kidney disease A BMI of 27 or higher, with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease Beneficiaries who already have GLP-1 coverage under Part D for a separate condition, such as type 2 diabetes or sleep apnea, arent eligible for the Bridge